Veterinary pharmacovigilance can quickly become resource-intensive as companies work to maintain continuous oversight of veterinary product safety. Marketing authorisation holders must ensure appropriate pharmacovigilance expertise and keep their systems compliant, even when internal teams are already stretched or specialist veterinary PV resources are limited.
For companies that need additional expertise or capacity, a large CRO may appear to be the obvious solution. But a broad outsourcing model is not always the best fit. Some organisations need targeted specialist support, direct access to veterinary PV expertise and a flexible model that complements their existing team rather than replacing it.
This is where veterinary pharmacovigilance consulting can provide a more tailored approach. Specialist support can be aligned with the company’s existing pharmacovigilance system, portfolio, internal capabilities and specific resource gaps, while maintaining clear responsibilities and appropriate oversight.
For companies searching for alternatives to large pharma CROs for vet safety monitoring, the real question is not simply who can take on the work. It is which model provides the right combination of veterinary expertise, flexibility, continuity and regulatory compliance. This article explores when specialised consulting may be the better fit and how Billev Pharma East can support veterinary pharmaceutical companies with flexible, expert-led pharmacovigilance solutions.
What should companies do before choosing external veterinary pharmacovigilance support?
Before deciding between a large CRO and specialised veterinary pharmacovigilance consulting, companies should first determine what support they actually need. When considering veterinary pharmacovigilance outsourcing, the goal should not be to transfer as many activities as possible, but to identify where external expertise can strengthen the existing pharmacovigilance organisation.Start by assessing your current PV capabilities, available resources, product portfolio and geographic coverage. Identify where internal teams have sufficient expertise and capacity and where gaps could create operational or compliance risks. These may arise from limited veterinary-specific expertise, increasing workloads, portfolio expansion or the need for additional support during specific projects or periods.
The next step is to define the scope of external support. Companies should establish which responsibilities will remain internal, which activities will be supported externally and how the external experts will interact with the internal team. Responsibilities, timelines, safety-data exchange, communication and escalation pathways, quality oversight and audit arrangements should be clearly defined.
This is particularly important because outsourcing does not transfer the ultimate pharmacovigilance responsibility away from the marketing authorisation holder. EU veterinary pharmacovigilance requirements expect outsourced activities to be clearly defined, agreed and controlled, with detailed contractual arrangements establishing responsibilities between the MAH and the external party.
A well-defined scope also makes it easier to determine whether a broad CRO model is actually necessary or whether flexible, specialist veterinary pharmacovigilance consulting can address the organisation’s needs more efficiently.
Why choose Billev Pharma East instead of a large CRO model?
Not every veterinary pharmaceutical company needs a large CRO structure to strengthen its safety operations. A large CRO can provide extensive infrastructure, but veterinary pharmaceutical companies do not always need an extensive outsourcing structure. When the challenge is a specific expertise gap, additional senior capacity or the need to strengthen an existing PV system, a specialised consulting model can provide a more focused solution.
This is the approach behind veterinary pharmacovigilance consulting at Billev Pharma East. As a specialised veterinary pharmacovigilance service provider, we start with your existing organisation rather than with a predefined package of outsourced services. Our experts can assess where additional veterinary PV knowledge or capacity is needed and shape the support around your products, markets, internal resources and responsibilities.
Our role is to bring the missing expertise into your existing structure without adding unnecessary complexity. This gives you access to specialised veterinary pharmacovigilance, regulatory and quality expertise while allowing the level of support to evolve with your portfolio, workload and internal capabilities.
Billev Pharma East combines veterinary pharmacovigilance expertise with regulatory and quality knowledge, allowing us to support both the immediate need and the wider context behind it. Our involvement can evolve as your portfolio, workload or internal capabilities change.
Instead of fitting your pharmacovigilance needs into a large CRO model, we help build the support model around your organisation.
What matters when looking for an alternative to a large CRO?
When considering alternatives to large pharma CROs for vet safety monitoring, companies should focus less on the size of the provider and more on whether the support model matches their actual pharmacovigilance needs.
A large-scale service structure may be appropriate when extensive operational infrastructure is required across multiple products, markets and activities. However, companies with established internal capabilities may need something different: specialist veterinary expertise, additional capacity for a defined scope or targeted support in areas such as veterinary signal detection that can integrate directly with the existing pharmacovigilance organisation.
The key is to define what problem the external partner needs to solve. Is the company missing specific veterinary PV expertise? Does the internal team need additional capacity? Is support required continuously or only for particular activities or periods? How much strategic and operational control does the company want to retain?
The answers help determine whether the company requires a broad operational outsourcing structure or a more focused consulting relationship.
The best alternative to a large CRO is therefore not necessarily another CRO. It may be a specialised consulting model built around the capabilities your organisation actually needs.
When does veterinary pharmacovigilance consulting make more sense than a large CRO?
Veterinary pharmacovigilance consulting can be a particularly good fit when a company already has part of the required pharmacovigilance infrastructure in place but needs specialist expertise to strengthen, complement or guide its internal capabilities.
The distinction is important. Not every organisation looking for external support needs to transfer an extensive package of activities to a large CRO. A company may instead face a specific knowledge gap, need additional expertise in areas such as veterinary safety case management, require specialist input on a complex veterinary safety issue or need temporary senior-level support as its portfolio or regulatory responsibilities evolve.
Consulting can also make sense when the company wants to remain closely involved in its pharmacovigilance activities. Consulting can also make sense when the company wants to remain closely involved in its pharmacovigilance activities and needs external expertise to complement rather than replace its existing capabilities.This makes the level of integration particularly important. External expertise should strengthen the existing pharmacovigilance system rather than create an additional layer between the company and its safety responsibilities.
The right model ultimately depends on the gap that needs to be solved. If the primary need is specialised knowledge, strategic guidance or precisely targeted additional expertise, a consulting model may offer a more proportionate solution than a broad CRO structure.
For veterinary pharmaceutical companies, the question is therefore not simply how much can we outsource? It is what expertise do we need to make our existing pharmacovigilance organisation stronger?
How do you keep veterinary pharmacovigilance consulting compliant?
Using veterinary pharmacovigilance consulting does not reduce a company’s regulatory responsibilities. The marketing authorisation holder remains ultimately responsible for its pharmacovigilance obligations, even when specific activities are performed by external specialists.
Compliance therefore starts with a clear operating framework. The responsibilities of the MAH and external consultant should be defined in written agreements, together with the activities covered, applicable products and territories, timelines, communication pathways and arrangements for any further subcontracting. Clear governance is particularly important for QPPV and veterinary pharmacovigilance, as the QPPV should maintain appropriate oversight of the pharmacovigilance system and relevant contractual arrangements. Relevant contractual arrangements and delegated activities must also be accurately reflected in the pharmacovigilance system master file (PSMF).
Oversight should continue throughout the relationship. Companies need mechanisms to verify that external activities are performed to the required quality standards and that the external team has sufficient capacity and appropriate quality controls. Third parties performing pharmacovigilance activities must also accept audits by or on behalf of the MAH, while relevant external personnel need appropriate pharmacovigilance training.
Where appropriate, companies should also define measurable indicators for the performance and quality of contracted pharmacovigilance activities.
This is particularly important when adopting a more flexible consulting model. Flexibility should never mean unclear ownership or fragmented processes. Instead, the consulting relationship should become a controlled and documented part of the company’s wider pharmacovigilance system.
A well-designed model therefore combines the advantages of specialised external expertise with clear governance, documented responsibilities and continuous MAH oversight.
Choose the right veterinary pharmacovigilance support model
The right veterinary pharmacovigilance partner is not necessarily the largest one. It is the one that gives your organisation the expertise it needs without adding unnecessary complexity.
For companies considering alternatives to large pharma CROs for vet safety monitoring, specialised veterinary pharmacovigilance consulting can offer a focused way to strengthen internal capabilities without adopting a broader support model than necessary.
At Billev Pharma East, we tailor our veterinary pharmacovigilance support to your organisation, portfolio and specific needs. Looking for an alternative to a large CRO? Contact Billev Pharma East to discuss how our veterinary pharmacovigilance consulting expertise can support your team, portfolio and regulatory responsibilities.
Sources: 1 – European Medicines Agency (EMA). Veterinary good pharmacovigilance practices (VGVP), 2 – European Medicines Agency (EMA). Guideline on veterinary good pharmacovigilance practices (VGVP) – Module: Pharmacovigilance systems, their quality management systems and pharmacovigilance system master files, 3 – European Medicines Agency (EMA). Veterinary pharmacovigilance inspections: Q&As, 4 – European Medicines Agency (EMA).Pharmacovigilance (veterinary medicines).